I would just add that at more of an operational level, now when we approve an new opioid and it reaches the NOC stage, when it gets to notice of compliance, we're making sure that we're sending out information to a number of affected parties, provincial-level bodies as well as pharmacists and physician associations, so that they are aware that a new opioid or a new change in indication has hit the landscape of opioid medication. They can reflect on that and better prepare how they might strategize at a provincial level to ensure that this product doesn't end up being abused, or they can risk manage how this might roll out and be used with the various hospital levels and patient groups.
On November 6th, 2013. See this statement in context.